Citadel Advisors
SLN

Citadel Advisors’s Silence Therapeutics SLN Stock Holding History

Citadel Advisors’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,300
Closed -$3.67K – 14851
2025
Q1 		$3.67K Buy
1,300
+800
+160% +$3.91K ﹤0.01% 13949
2024
Q4 		$3.44K Buy
500
+200
+67% +$2.58K ﹤0.01% 13994
2024
Q3 		$5.45K Buy
+300
New +$5.58K ﹤0.01% 13487

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Citadel Advisors's SLN Position: Q2 2026 in Review

Citadel Advisors increased its Silence Therapeutics (SLN) stake by 7.7% in Q2 2026, buying an estimated $667K and bringing the position to 1,329,625 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3011.

Citadel Advisors first reported a position in SLN in Q2 2022 and has held it in 12 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Citadel Advisors held 1,329,625 shares of Silence Therapeutics worth $14.6M as of Q2 2026.
  • Citadel Advisors bought 94,818 Silence Therapeutics shares in Q2 2026, an estimated $667K.
  • Silence Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3011 holding.
  • Citadel Advisors first reported a position in Silence Therapeutics in Q2 2022 and has held it in 12 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.